Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Single Rising Doses of BI 765423 in Healthy Males
NCT05658107Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2023
- Primary completion
- Mar 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in idiopathic pulmonary fibrosis (IPF) comparing BI 765423 with Placebo (2 arms). Primary endpoint: Occurrence of any treatment-emergent adverse event assessed as drug-related by the investigator up to 183 days. Started Jan 2023; status: completed.
02
Drugs
BI-765423
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05658107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05658107.